[
  {
    "ts": null,
    "headline": "Amgen (AMGN) Stock Sinks As Market Gains: Here's Why",
    "summary": "Amgen (AMGN) reached $294.12 at the closing of the latest trading day, reflecting a -1.27% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=b57e1d377f3810f21c20aa9ecf34b40e6d34d62a4dc4813817d34a1d030c7d4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759787402,
      "headline": "Amgen (AMGN) Stock Sinks As Market Gains: Here's Why",
      "id": 136999211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) reached $294.12 at the closing of the latest trading day, reflecting a -1.27% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=b57e1d377f3810f21c20aa9ecf34b40e6d34d62a4dc4813817d34a1d030c7d4d"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Slashes Drug Price After Trump Threat--Repatha Now 60% Cheaper Online",
    "summary": "Biotech giant rushes to comply with Trump's drug price crackdown, joins Pfizer in avoiding tariff backlash",
    "url": "https://finnhub.io/api/news?id=f29ad165f1c995e45e0fa9b6d3d2ccf40d7eab6b0be08127915a1f500dca3ad0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759778582,
      "headline": "Amgen Slashes Drug Price After Trump Threat--Repatha Now 60% Cheaper Online",
      "id": 136989538,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Biotech giant rushes to comply with Trump's drug price crackdown, joins Pfizer in avoiding tariff backlash",
      "url": "https://finnhub.io/api/news?id=f29ad165f1c995e45e0fa9b6d3d2ccf40d7eab6b0be08127915a1f500dca3ad0"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock underperforms Monday when compared to competitors",
    "summary": "Amgen Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=87644d81b6711089752cffbc803ae4f7999aa2998ea4e628071177ac63b61e98",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759768500,
      "headline": "Amgen Inc. stock underperforms Monday when compared to competitors",
      "id": 137016655,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=87644d81b6711089752cffbc803ae4f7999aa2998ea4e628071177ac63b61e98"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts",
    "summary": "The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.",
    "url": "https://finnhub.io/api/news?id=3a8aba5b3219f66fad40d547e5d235f59ee1f45972171d7d536c4a7dac83e7f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759763340,
      "headline": "Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts",
      "id": 136989539,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.",
      "url": "https://finnhub.io/api/news?id=3a8aba5b3219f66fad40d547e5d235f59ee1f45972171d7d536c4a7dac83e7f9"
    }
  },
  {
    "ts": null,
    "headline": "Bullous Pemphigoid Market Analysis and Forecast Report 2025-2035",
    "summary": "Emerging technologies in diagnostics and telemedicine are transforming patient management, although high costs and variable patient responses remain barriers. With growing investments in dermatological research, demand is driven by the aging population and advanced diagnostic techniques. Key market players include Sanofi, Regeneron, and Amgen.Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The \"Bullous Pemphigoid Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and",
    "url": "https://finnhub.io/api/news?id=afc2140e94d256ab0401bbbf268fa5ae9f9b3695371c319e739b817210ad6572",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759758780,
      "headline": "Bullous Pemphigoid Market Analysis and Forecast Report 2025-2035",
      "id": 136989540,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Emerging technologies in diagnostics and telemedicine are transforming patient management, although high costs and variable patient responses remain barriers. With growing investments in dermatological research, demand is driven by the aging population and advanced diagnostic techniques. Key market players include Sanofi, Regeneron, and Amgen.Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The \"Bullous Pemphigoid Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and",
      "url": "https://finnhub.io/api/news?id=afc2140e94d256ab0401bbbf268fa5ae9f9b3695371c319e739b817210ad6572"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Amgen (AMGN) is a Strong Value Stock",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=9b32abf1f52700e0d9ca951f39687dc04c9814e888d817de53f504c0b1ebd826",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759758002,
      "headline": "Here's Why Amgen (AMGN) is a Strong Value Stock",
      "id": 136989541,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=9b32abf1f52700e0d9ca951f39687dc04c9814e888d817de53f504c0b1ebd826"
    }
  },
  {
    "ts": null,
    "headline": "My Top 5 Biotech Stocks Big Pharma Could Buy Next",
    "summary": "Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.",
    "url": "https://finnhub.io/api/news?id=0615cc217ad0cd350a198a8133c50199b31af463e4f96ab378a062934e7cccc8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759757340,
      "headline": "My Top 5 Biotech Stocks Big Pharma Could Buy Next",
      "id": 136988239,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1146642361/image_1146642361.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.",
      "url": "https://finnhub.io/api/news?id=0615cc217ad0cd350a198a8133c50199b31af463e4f96ab378a062934e7cccc8"
    }
  },
  {
    "ts": null,
    "headline": "GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings",
    "summary": "SANTA MONICA, Calif., October 06, 2025--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a cholesterol-lowering therapy, at a significantly reduced cash price. Starting today, patients can use GoodRx to access Repatha for $239 at more than 70,000 pharmacies nationwide, a savings of nearly 60% off the retail pharmacy list price.",
    "url": "https://finnhub.io/api/news?id=ac5234b51280dff19215ae62a6df64f741a52e8bf4872d82c9bb225ec4669e8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759756500,
      "headline": "GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings",
      "id": 136989542,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "SANTA MONICA, Calif., October 06, 2025--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a cholesterol-lowering therapy, at a significantly reduced cash price. Starting today, patients can use GoodRx to access Repatha for $239 at more than 70,000 pharmacies nationwide, a savings of nearly 60% off the retail pharmacy list price.",
      "url": "https://finnhub.io/api/news?id=ac5234b51280dff19215ae62a6df64f741a52e8bf4872d82c9bb225ec4669e8b"
    }
  },
  {
    "ts": null,
    "headline": "Is There An Opportunity With Amgen Inc.'s (NASDAQ:AMGN) 49% Undervaluation?",
    "summary": "Key Insights The projected fair value for Amgen is US$586 based on 2 Stage Free Cash Flow to Equity Current share price...",
    "url": "https://finnhub.io/api/news?id=076af6828cbfbd96e15cb10d2de6fee1aa5ce9264031602c2efdc478ce547d73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759755610,
      "headline": "Is There An Opportunity With Amgen Inc.'s (NASDAQ:AMGN) 49% Undervaluation?",
      "id": 136989543,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Key Insights The projected fair value for Amgen is US$586 based on 2 Stage Free Cash Flow to Equity Current share price...",
      "url": "https://finnhub.io/api/news?id=076af6828cbfbd96e15cb10d2de6fee1aa5ce9264031602c2efdc478ce547d73"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.",
    "summary": "Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolucumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial.",
    "url": "https://finnhub.io/api/news?id=b77e1a47ea81a986fa05216bf405a4065b552f3991ebcfc82205b0a11fd165b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759755600,
      "headline": "AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.",
      "id": 136989544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolucumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial.",
      "url": "https://finnhub.io/api/news?id=b77e1a47ea81a986fa05216bf405a4065b552f3991ebcfc82205b0a11fd165b8"
    }
  }
]